| Code | CSB-RA858415MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Romosozumab-AQQG, targeting sclerostin (SOST), a glycoprotein secreted primarily by osteocytes that functions as a key negative regulator of bone formation. SOST inhibits the Wnt signaling pathway by binding to LRP5/6 co-receptors on osteoblasts, thereby suppressing bone formation and reducing bone mineral density. Dysregulation of SOST expression is associated with various skeletal disorders, including osteoporosis, osteopenia, and conditions characterized by low bone mass and increased fracture risk.
Romosozumab-AQQG is a humanized IgG2 monoclonal antibody that binds to and neutralizes sclerostin, leading to increased bone formation and decreased bone resorption. This biosimilar antibody serves as a valuable research tool for investigating sclerostin biology, bone remodeling mechanisms, Wnt pathway modulation, and skeletal disease pathophysiology. It enables researchers to explore therapeutic mechanisms relevant to bone metabolism disorders and evaluate potential interventions targeting the SOST pathway in preclinical models and in vitro systems.
There are currently no reviews for this product.